A recent study assessed sTM, vWF, and IL-6 in renal transplant recipients (RTRs) and associated their plasma levels with primary cause of end-stage renal disease (ESRD) and allograft function.181They found that sTM and IL-6 could be used as potential markers for evaluating renal graft function. The gene discussed is IL6; the disease is stage 5 chronic kidney disease.